Imukin

Recombinant Human Interferon Gamma 1b, the active ingredient in Imukin, is an Interferon presented as a lyophilized powder for injection for subcutaneous use. It is indicated for chronic granulomatous disease and severe malignant osteopetrosis, where it modulates immune function and bone remodeling. GNH USA supplies Imukin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Imukin is an interferon‑gamma product that acts on immune‑deficiency and bone‑remodeling pathways. - Chronic granulomatous disease: enhances macrophage killing capacity to reduce recurrent infections. - Severe malignant osteopetrosis: stimulates osteoclast activity to improve bone resorption and alleviate disease severity.

Interferon‑gamma therapy is associated with a range of adverse reactions.

Common Side Effects: - Flu‑like symptoms: fever, chills, and muscle aches. - Injection‑site reactions: redness, swelling, or pain at the site. - Fatigue and headache. - Nausea or mild gastrointestinal upset.

Serious or Rare Side Effects: - Hematologic abnormalities such as neutropenia or anemia. - Elevated liver enzymes indicating hepatic stress. - Autoimmune phenomena, including lupus‑like syndrome. - Severe allergic reactions or anaphylaxis. - Pulmonary toxicity presenting as dyspnea or interstitial lung changes.

Patients receiving Imukin should be monitored for safety and efficacy. - Blood counts: regularly assess for neutropenia or anemia. - Liver function: monitor transaminases during therapy. - Autoimmune disease: evaluate for new or worsening autoimmune symptoms. - Cardiac status: use cautiously in patients with severe cardiac disease. - Hypersensitivity: discontinue if a serious allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Interferon‑gamma can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Live vaccines: increased risk of infection due to immune modulation. - High‑dose corticosteroids or other potent immunosuppressants: may diminish therapeutic effect. - Anticoagulants (e.g., warfarin): potential for enhanced bleeding risk.

Moderate Interactions (Monitor Closely): - CYP450 substrates: possible alteration of metabolism. - Antihistamines: may mask fever, a common side effect. - Concurrent interferons or other immunomodulators: additive toxicity risk.